NCT05388695

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).

Detailed description

This study is open single-arm prospective clinical study To relapse/refractory blood B cell tumor patients as the subjects, according to the expression of tumor cells, gives the corresponding double targets CART cell injection treatment, follow-up observation of the adverse reactions and the treatment effect of the drug to the data (at least 2 years), assessment of double targets CAR - T Long-term efficacy and safety of cell injection

Conditions

• 19 and 22+ B Cell Hematologic Tumors
• 19 and 20+ B Cell Hematologic Tumors

Interventions

Type	Name	Description
BIOLOGICAL	Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells	Single or sequential injection of CD19, CD20 and CD22 CAR T cells.

Timeline

• Start date: 2022-04-08
• Primary completion: 2027-03-30
• Completion: 2027-05-30
• First posted: 2022-05-24
• Last updated: 2025-06-18

Locations

1 site across 1 country: China